We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+13.54%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.12B
AUM Growth
-$493M
Cap. Flow
-$785M
Cap. Flow %
-15.35%
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$101M
2
RLAY icon
Relay Therapeutics
RLAY
+$70.2M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$59.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$39.8M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$33.2M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$122M
2
ACLX
Arcellx
ACLX
+$95.6M
3
BSX icon
Boston Scientific
BSX
+$93.3M
4
FOLD
Amicus Therapeutics
FOLD
+$90.7M
5
ATXS
Astria Therapeutics
ATXS
+$84.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$8.77B
$656M 12.82%
2,035,986
+40,000
+2% +$12.4M
CELC icon
2
Celcuity
CELC
$4.31B
$357M 6.97%
3,127,200
-33,000
-1% -$3.6M
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$350M 6.84%
1,531,421
+450,000
+42% +$101M
ROIV icon
4
Roivant Sciences
ROIV
$24.8B
$230M 4.48%
8,285,461
+300,000
+4% +$7.71M
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$209M 4.08%
5,258,903
+2,341,269
+80% +$59.9M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.31B
$206M 4.03%
2,373,795
-172,596
-7% -$16.8M
SYRE icon
7
Spyre Therapeutics
SYRE
$8.7B
$191M 3.73%
3,783,225
+714,000
+23% +$26.9M
NUVL
8
DELISTED
Nuvalent
NUVL
$162M 3.16%
1,580,505
-84,600
-5% -$8.62M
EWTX icon
9
Edgewise Therapeutics
EWTX
$4.28B
$139M 2.72%
4,423,974
-34,000
-0.8% -$980K
PTGX icon
10
Protagonist Therapeutics
PTGX
$9.06B
$130M 2.54%
1,230,879
-119,546
-9% -$10.6M
APGE icon
11
Apogee Therapeutics
APGE
$10.1B
$130M 2.53%
1,540,384
-790,267
-34% -$57.4M
TVTX icon
12
Travere Therapeutics
TVTX
$5.27B
$123M 2.41%
4,142,551
-135,629
-3% -$4.05M
AMLX icon
13
Amylyx Pharmaceuticals
AMLX
$1.97B
$115M 2.25%
8,284,882
– –
IMTX icon
14
Immatics
IMTX
$1.31B
$102M 2%
10,383,456
– –
RLAY icon
15
Relay Therapeutics
RLAY
$4.34B
$97M 1.9%
9,751,141
+7,847,896
+412% +$70.2M
INBX icon
16
Inhibrx
INBX
$1.28B
$97M 1.9%
1,442,707
-10,000
-0.7% -$742K
MGTX icon
17
MeiraGTx Holdings
MGTX
$1.15B
$89.3M 1.75%
10,326,103
– –
ZYME icon
18
Zymeworks
ZYME
$1.78B
$87.9M 1.72%
3,510,078
+248,228
+8% +$5.87M
SLDB icon
19
Solid Biosciences
SLDB
$858M
$85.7M 1.68%
11,906,646
+73,107
+0.6% +$470K
DYN icon
20
Dyne Therapeutics
DYN
$3.92B
$84.6M 1.65%
4,668,839
+1,189,895
+34% +$20.5M
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.36B
$70.8M 1.38%
7,434,033
+4,271,504
+135% +$33.2M
ORKA
22
Oruka Therapeutics
ORKA
$5.59B
$68.4M 1.34%
1,395,501
-81,000
-5% -$2.82M
AORT icon
23
Artivion
AORT
$1.22B
$60M 1.17%
1,637,290
-85,000
-5% -$3.35M
NRIX icon
24
Nurix Therapeutics
NRIX
$2.4B
$57.5M 1.12%
3,710,877
+155,000
+4% +$2.57M
MRNA icon
25
PUT
Moderna
MRNA
$24.5B
$50.8M 0.99%
+1,000,000
New +$46.7M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $785M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.

  • Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
  • Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
  • Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
  • Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
  • Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.